Contact Supplier

Contact Supplier

To get in touch with enGenes Biotech GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    enGenes Biotech brings latest downstream production solutions and COVID-19 antigens to BIO-Europe Digital

    news-releasesenGenes Biotech GmbH
    October 13th 2020

    Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) will present its latest expression technologies online at the BIO Europe DIGITAL virtual convention later this month.

    enGenes will use the event’s advanced networking platforms to discuss latest applications of its enhanced expression yield enGenes-eXpress production platform. It will also highlight its ongoing R&D projects to find partners for further development and present its program to commercialize the premium quality SARS CoV-2 Antigens (Nucleocapsid Protein, Receptor Binding Domain (RBD), Spike Protein, S1+S2) that it is producing for use in serological testing or R&D.

    Maintaining support

    enGenes is a well-established presence at BIO-Europe events and wished to maintain support for the event despite COVID-19 forcing cancellation of the physical event in Paris.

    “We welcome requests from biotech companies of all kinds and sizes via the event’s partneringONE platform to get into discussion about possible collaborations,” said Dr. Mairhofer.

    “We welcome new partners for feasibility studies and process development projects that can harness the huge benefits of using enGenes-eXpress technology and our auxiliary know-how for manufacturing of new products as well as progressing further development projects that will tailor our technology to specific needs,” he added.

    “We can offer very cost-effective manufacturing solutions with our enGenes-eXpress technology offering protein secretion allowing cost-effective downstream processing from E. coli cell free supernatants. We can also put partners in touch with our dedicated team of experts to discuss our innovative bioconjugation solution that can specifically modify recombinant proteins,” Dr. Mairhofer explained.

    About enGenes Biotech

    enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

    enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

    enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

    About BIO Europe DIGITAL 2020

    The biannual BIO-Europe events are premier partnering conferences dedicated to driving forward partnering in the life sciences sector. They attract an international “who’s who” from biotech, pharma and finance for high caliber networking.

    As with BIO-Europe Spring earlier this year, the originally scheduled four-day physical event has been repurposed as a COVID-19 friendly digital online edition, using forums, webinars and video conferencing technology to allow the same networking and knowledge sharing benefits as the ‘live’ event, along with the sophisticated partneringONE® platform to enable networking and meetings between financiers, innovators and companies across the life science value chain, from large biotech to start-ups.

    BIO Europe will remain a four-day event, opening October 26, that will provide intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. The event will feature more than 40 presentations spread across five streams, including Biotech Ecosystem, Business Development, Microbiome Therapeutics and Therapeutic applications.

    BIO Europe DIGITAL is organized by the EBD Group in association with the Washington DC-based Biotechnology Innovation Organization. Further information at:


    Click on enGenes Biotech recombinant protein production for more information.


    Meet the Partners - Co-Founder - Juergen Mairhofer

    enGenes Biotech brings latest downstream production solutions and COVID-19 antigens to BIO-Europe Digital

    Contact enGenes Biotech GmbH

    Simply fill out the form below to contact enGenes Biotech GmbH now.

    Send enGenes Biotech GmbH a Message